Cellular nanosponges inhibit SARS-CoV-2 infectivity

Summary

This antiviral study develops host-cell-mimicking nanosponges as decoys for SARS-CoV-2. The particles were coated with plasma membranes from either human type II lung epithelial cells or human macrophages. These natural membranes carry the collection of known and unidentified host proteins used by the virus for cellular entry. By presenting those receptors on a nonliving nanoscale target, the formulation was designed to attract virions away from susceptible cells. Incubation with either nanosponge type neutralized SARS-CoV-2 and prevented subsequent cellular infection in the reported system. The principal finding is that preserving a target cell's receptor landscape on a nanoparticle can create a broad decoy without identifying and separately incorporating every entry factor. The authors further argue that this mechanism should be less sensitive to viral mutation than a strategy aimed at one viral epitope, provided the virus continues to use the same host-cell type and its receptors. The significance is a potentially adaptable countermeasure based on host identity rather than viral sequence. The concise abstract does not report the experimental model, neutralization potency, in vivo efficacy, pharmacology, safety, or direct evidence across variants or other viral species.